| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Division of Psychiatric Neuroimaging (Drs. Aylward, Li, Barta, and Pearlson), the Baltimore Huntington's Disease Center (Drs. Aylward, Li, Stine, Ranen, Bylsma, and Ross, and M. Sherr), and the Department of Neuroscience (Dr. Ross), Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
Supported by grants from the NINDS (16375), NIH Division of Research Resources/Johns Hopkins Outpatient Clinical Research Center (RR00722), and the Huntington's Disease Society of America.
Received May 7, 1996. Accepted in final form July 3, 1996.
Address correspondence and reprint requests to Elizabeth H. Aylward, PhD, Meyer 3-166, The Johns Hopkins University School of Medicine, 600 North Wolfe St., Baltimore, MD 21287-7362.
Article abstract-Cross-sectional MRI studies demonstrating an association between caudate atrophy and symptom severity and duration of symptoms in patients with Huntington's disease (HD) have been assumed to reflect longitudinal changes in basal ganglia, but such neuropathologic progression has never been directly demonstrated. Subjects in the current study were 23 HD patients at various stages of the disorder who had two MRI images at least 10 months apart (mean interimage interval = 20.8 months). We measured volumes of caudate, putamen, and globus pallidus blind to the order of the images. For each structure, we calculated a change score by subtracting the volume obtained on the follow-up imaging from that obtained on the initial imaging. Results indicated significant decreases over time in caudate, putamen, and total basal ganglia volume. Age at onset and length of trinucleotide repeat correlated significantly with amount of volume change in caudate and total basal ganglia, even after controlling for length of interimage interval, duration of disease, and measures of symptom severity. Amount of change in basal ganglia structures was not significantly correlated with neurologic symptom severity at the time of the initial imaging or duration of symptoms. This is the first longitudinal MRI study to document progressive basal ganglia atrophy in HD, and suggests that quantitative neuroimaging with serial MRI may be useful in monitoring effectiveness of potential treatments. In addition, demonstration of greater rate of basal ganglia atrophy in patients with earlier symptom onset suggests that treatment effects may be more quickly observed in this subgroup of patients than in the general HD population.
NEUROLOGY 1997;48: 394-399
This article has been cited by other articles:
|
|
 |
|
  H H Ruocco, L Bonilha, L M Li, I Lopes-Cendes, and F Cendes Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat J. Neurol. Neurosurg. Psychiatry, February 1, 2008; 79(2): 130 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Johnson, J. C. Stout, A. C. Solomon, D. R. Langbehn, E. H. Aylward, C. B. Cruce, C. A. Ross, M. Nance, E. Kayson, E. Julian-Baros, et al. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease Brain, July 1, 2007; 130(7): 1732 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Paulsen, M. Hayden, J. C. Stout, D. R. Langbehn, E. Aylward, C. A. Ross, M. Guttman, M. Nance, K. Kieburtz, D. Oakes, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol, June 1, 2006; 63(6): 883 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rosenblatt, K. -Y. Liang, H. Zhou, M. H. Abbott, L. M. Gourley, R. L. Margolis, J. Brandt, and C. A. Ross The association of CAG repeat length with clinical progression in Huntington disease Neurology, April 11, 2006; 66(7): 1016 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Berglund and R. Ramakrishnan Lipoprotein(a): An Elusive Cardiovascular Risk Factor Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2219 - 2226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fennema-Notestine, S. L. Archibald, M. W. Jacobson, J. Corey-Bloom, J. S. Paulsen, G. M. Peavy, A. C. Gamst, J. M. Hamilton, D. P. Salmon, and T. L. Jernigan In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease Neurology, September 28, 2004; 63(6): 989 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Aylward, B. F. Sparks, K. M. Field, V. Yallapragada, B. D. Shpritz, A. Rosenblatt, J. Brandt, L. M. Gourley, K. Liang, H. Zhou, et al. Onset and rate of striatal atrophy in preclinical Huntington disease Neurology, July 13, 2004; 63(1): 66 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Kassubek, F D Juengling, T Kioschies, K Henkel, J Karitzky, B Kramer, D Ecker, J Andrich, C Saft, P Kraus, et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study J. Neurol. Neurosurg. Psychiatry, February 1, 2004; 75(2): 213 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Margolis and C. A. Ross Diagnosis of Huntington Disease Clin. Chem., October 1, 2003; 49(10): 1726 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Marder, S. Sandler, A. Lechich, J. Klager, and S.M. Albert Relationship between CAG repeat length and late-stage outcomes in Huntington's disease Neurology, November 26, 2002; 59(10): 1622 - 1624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Thieben, A. J. Duggins, C. D. Good, L. Gomes, N. Mahant, F. Richards, E. McCusker, and R. S. J. Frackowiak The distribution of structural neuropathology in pre-clinical Huntington's disease Brain, August 1, 2002; 125(8): 1815 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Brown, L. Redondo-Verge, J. R. Chacon, M. L. Lucas, and S. Channon Dissociation between intentional and incidental sequence learning in Huntington's disease Brain, November 1, 2001; 124(11): 2188 - 2202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Rosas, J. Goodman, Y. I. Chen, B. G. Jenkins, D. N. Kennedy, N. Makris, M. Patti, L. J. Seidman, M. F. Beal, and W. J. Koroshetz Striatal volume loss in HD as measured by MRI and the influence of CAG repeat Neurology, September 25, 2001; 57(6): 1025 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Y. Hsu, A.-T. Du, N. Schuff, and M. W. Weiner Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy in Dementias J Geriatr Psychiatry Neurol, September 1, 2001; 14(3): 145 - 166. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J. Lang, L. C. Kopala, R. A. Vandorpe, Q. Rui, G. N. Smith, V. M. Goghari, and W. G. Honer An MRI Study of Basal Ganglia Volumes in First-Episode Schizophrenia Patients Treated With Risperidone Am J Psychiatry, April 1, 2001; 158(4): 625 - 631. [Abstract] [Full Text]
|
|
|
|
|
|
R. Sanchez-Pernaute, J. M. Garcia-Segura, A. del Barrio Alba, J. Viano, and J. G. de Yebenes Clinical correlation of striatal 1H MRS changes in Huntington's disease Neurology, September 1, 1999; 53(4): 806 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kremer, C. M. Clark, E. W. Almqvist, L. A. Raymond, P. Graf, C. Jacova, M. Mezei, M. A. Hardy, B. Snow, W. Martin, et al. Influence of lamotrigine on progression of early Huntington disease: A randomized clinical trial Neurology, September 1, 1999; 53(5): 1000 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Foroud, J. Gray, J. Ivashina, and P M. Conneally Differences in duration of Huntington's disease based on age at onset J. Neurol. Neurosurg. Psychiatry, January 1, 1999; 66(1): 52 - 56. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Gilman Imaging the Brain- Second of Two Parts N. Engl. J. Med., March 26, 1998; 338(13): 889 - 896. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
